-
- Fellows 2024-2025
- Fellows 2023-2024
- Fellows 2022-2023
- Fellows 2021-2022
- Fellows 2020-2021
- Fellows 2019-2020
- Fellows 2018-2019
- Fellows 2017-2018
- Fellows 2016-2017
- Fellows 2015-2016
- Fellows 2014-2015
- Fellows 2013-2014
- Fellows 2012-2013
- Fellows 2011-2012
- Fellows 2010-2011
- Fellows 2009-2010
- Fellows 2008-2009
- Scientific activities
You are here : Version anglaise > Fellows > Fellows 2022-2023
-
Partager cette page
Séjour court
Aparecida Maria
Aparecida Maria
FONTES
Genetics - Brazil>
Contact details
- Email.
- aparecidamfontes@usp.br
- Personal Website.
- http://rge.fmrp.usp.br/mostra_docentes.php
Research topics
PROJECT
Development of a mRNA-based vaccine against SARS-COV-2 encoding multiple epitopes and using Lipo Particle as innovative carrierRecently, twomRNA-based vaccines have been crucial for ending the ongoingseverepandemic of COVID-19. However, these vaccines encode only the spikeglycoprotein of SARS-CoV-2 and as the spikegeneis a mutation hotspot, hence at risk of losingsome of theirefficacywhen SARS-CoV-2 variantsemerge. Additionally, thesecurrentmRNA vaccines utilizelipidnanoparticletechnology,howeverhybrid carrier systemsprovide more flexibility and greaterfunctionalitycompared to non-hybridsystems. Withthis in mind, the proposedproject has 3 main objectives: 1) formulating a mRNA-based vaccine thatprovides protection against the SARS-CoV-2 pathogeninduced in response to antigensfromthree structural proteins; 2) includesignificant modifications of the mRNA structure in the production of IVT-mRNA to improvemRNA translation efficiency and overcome the innateimmunogenicity and 3) use LipoParticle as delivery system whichallowthe use of low doses of mRNA and enhanceendosomal escape.
Activities / Resume
BIOGRAPHY
Aparecida Maria Fontes is Assistant Professor at Genetics Department of Ribeirão Preto School of Medicine of University of São Paulo. Dr. Fontes interest is genetherapy, epigenetics and mRNA vaccine.PARTNER LABORATORY
CO-SPONSORS
DATES OF STAY
September 2022 to January 2023
KEY WORDS
• COVID-19 mRNA vaccine
• LipoParticle delivery system
• multiple epitopes